Intellia Therapeutics, Inc. (NTLA) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $14.60 (-2.18%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 27, 2026 | Jack Allen | Robert W. Baird | $7.00 | -52.1% |
| Oct 30, 2025 | David Nierengarten | Wedbush | $9.00 | -38.4% |
| Oct 30, 2025 | Mitchell Kapoor | H.C. Wainwright | $18.00 | +23.3% |
| Oct 30, 2025 | Jack Allen | Robert W. Baird | $9.00 | -38.4% |
| Oct 28, 2025 | Gena Wang | Barclays | $24.00 | +64.4% |
| Oct 28, 2025 | William Pickering | Tudor Pickering | $14.50 | -0.7% |
| Oct 28, 2025 | Luca Issi | RBC Capital | $14.00 | -4.1% |
| Oct 27, 2025 | Mitchell Kapoor | H.C. Wainwright | $25.00 | +71.2% |
| Oct 6, 2025 | Silvan Tuerkcan | JMP Securities | $33.00 | +126.0% |
| Aug 13, 2025 | Debjit Chattopadhyay | Guggenheim | $14.00 | -4.1% |
| Nov 11, 2024 | Jay Olson | Oppenheimer | $60.00 | +311.0% |
| Oct 24, 2024 | Jack Allen | Robert W. Baird | $18.00 | +23.3% |
| Aug 9, 2024 | Luca Issi | RBC Capital | $54.00 | +269.9% |
| Jun 24, 2024 | Dae Gon Ha | Stifel Nicolaus | $80.00 | +447.9% |
| Jun 24, 2024 | Jack Allen | Robert W. Baird | $24.00 | +64.4% |
| May 10, 2024 | Kostas Biliouris | BMO Capital | $70.00 | +379.4% |
| Jun 16, 2022 | Kostas Biliouris | BMO Capital | $54.00 | +269.9% |
| May 9, 2022 | Steven Seedhouse | Raymond James | $105.00 | +619.2% |
| Feb 24, 2022 | Luca Issi | RBC Capital | $150.00 | +927.4% |
| Feb 18, 2022 | Raju Prasad | William Blair | $144.00 | +886.3% |
Top Analysts Covering NTLA
NTLA vs Sector & Market
| Metric | NTLA | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.43 | 2.24 | 2.40 |
| Analyst Count | 23 | 8 | 19 |
| Target Upside | +113.7% | +11474.9% | +17.1% |
| P/E Ratio | -3.47 | 3.91 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $37M | $59M | $85M | 18 |
| 2027-12-31 | $2M | $256M | $2.05B | 17 |
| 2028-03-31 | $2M | $3M | $4M | 4 |
| 2028-06-30 | $3M | $4M | $6M | 6 |
| 2028-09-30 | $4M | $5M | $8M | 9 |
| 2028-12-31 | $4M | $7M | $10M | 4 |
| 2029-03-31 | $6M | $8M | $13M | 6 |
| 2029-06-30 | $7M | $11M | $16M | 8 |
| 2029-09-30 | $9M | $14M | $21M | 5 |
| 2029-12-31 | $11M | $17M | $25M | 5 |
| 2030-12-31 | $198M | $2.68B | $23.96B | 13 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-4.93 | $-3.62 | $-1.99 | 18 |
| 2027-12-31 | $-6.02 | $-2.00 | $24.68 | 16 |
| 2028-03-31 | $-1.31 | $-0.78 | $-0.45 | 5 |
| 2028-06-30 | $-1.13 | $-0.67 | $-0.39 | 7 |
| 2028-09-30 | $-1.14 | $-0.68 | $-0.40 | 10 |
| 2028-12-31 | $-1.15 | $-0.69 | $-0.40 | 5 |
| 2029-03-31 | $-1.16 | $-0.69 | $-0.40 | 5 |
| 2029-06-30 | $-1.04 | $-0.62 | $-0.36 | 7 |
| 2029-09-30 | $-1.04 | $-0.62 | $-0.36 | 4 |
| 2029-12-31 | $-1.04 | $-0.62 | $-0.36 | 4 |
| 2030-12-31 | $-1.96 | $9.62 | $108.91 | 5 |
Frequently Asked Questions
What is the analyst consensus for NTLA?
The consensus among 23 analysts covering Intellia Therapeutics, Inc. (NTLA) is Buy with an average price target of $20.88.
What is the highest price target for NTLA?
The highest price target for NTLA is $252.00, set by Salveen Richter at Goldman Sachs on 2021-08-06.
What is the lowest price target for NTLA?
The lowest price target for NTLA is $7.00, set by Jack Allen at Robert W. Baird on 2026-01-27.
How many analysts cover NTLA?
23 analysts have issued ratings for Intellia Therapeutics, Inc. in the past 12 months.
Is NTLA a buy or sell right now?
Based on 23 analyst ratings, NTLA has a consensus rating of Buy (2.43/5) with a +113.7% upside to the consensus target of $20.88.
What are the earnings estimates for NTLA?
Analysts estimate NTLA will report EPS of $-3.62 for the period ending 2026-12-31, with revenue estimated at $59M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.